Product Code: RP-ID-10265736 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10265736
Market Overview:
Global Nuclear Medicine/ Radiopharmaceuticals Market Size study, by Type (Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine), Application (Diagnostic Application and Therapeutic Application), by Procedural Volume (Diagnostic procedures and Therapeutic procedures) and Regional Forecasts 2019-2026
Global Nuclear Medicine/ Radiopharmaceuticals Market is valued approximately at USD 3.95 Billion in 2018 and is anticipated to grow with a growth rate of more than 5.90% over the forecast period 2019-2026. Nuclear medicine is medical specialty that uses radioactive tracers (radiopharmaceutical) to determine bodily function and to diagnose and treat disease. It is featured with designed camera that allows doctor to track the path of these radioactive trackers. In nuclear medication, Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) are common imaging scanning those are widely used in end-use industry. Nuclear medicine is implemented in human body by injecting radioactive material (radiopharmaceuticals or radiotracers) that can easily be detected on the PET scan. Radiotracers are commonly used in cancer treatment as it contains fluorodeoxyglucose that is a molecule like glucose. Cancer cells are metabolically active and absorb glucose at a higher speed that can easily be detected by PET scans. Therefore, efficient application of Nuclear medicine in cancer detection coupled with rising cancer cases across the globe accelerate the growth of market over the forecast years. For instance: According to the International Agency for Research on Cancer (IARC) 2018, over 17 Billion new cancer cases were registered in 2018. Additionally, increasing incidence and prevalence of target conditioning is the factor driving the growth of market over the upcoming years. Whereas, application of radiopharmaceuticals in neurological disorders is an opportunity for the market growth. However, short life of radiopharmaceuticals are the factors hamper the growth of market over the forecast years.
The regional analysis of global Nuclear Medicine/ Radiopharmaceuticals market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America accounts for the largest share in the global Nuclear Medicine market due to the increased better infrastructure facility in the health care sector. Similarly, North America is the fastest growing region in the market owing to the effectiveness of a diagnosis procedure for the early detection such as cancer and cardiac diseases.
Market player included in this report are:
Cardinal Health
Positron Corporation
GE Healthcare
Curium
Lantheus Medical Imaging
Bayer
Bracco Imaging
Eczacibasi-Monrol Nuclear Products
Nordion
Advanced Accelerator Applications
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Diagnostic Nuclear Medicine
Therapeutic Nuclear Medicine
By Application:
Diagnostic Application
Therapeutic application
By Procedural Volume:
Diagnostic procedures
Therapeutic procedures
By Regions:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2016, 2017
Base year – 2018
Forecast period – 2019 to 2026
Target Audience of the Global Nuclear Medicine/ Radiopharmaceuticals Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Positron Corporation
GE Healthcare
Curium
Lantheus Medical Imaging
Bayer
Bracco Imaging
Eczacibasi-Monrol Nuclear Products
Nordion
Advanced Accelerator Applications
Related Reports
Proof of Quality & Reliability
